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Abstract 
Objectives: To obtain consensus on minimum data items for an observational cohort study in 
rheumatoid arthritis (RA) in the UK and to make available the process for similar studies and 
other rheumatic conditions.  
Methods: Individuals with a diverse range of expertise and backgrounds were invited to 
participate in a process to propose a minimal core dataset (MCD) for research studies, 
commissioned by Arthritis Research UK as part of the larger INBANK project. The group 
included patients and representatives from clinical and academic rheumatology, outcomes 
science, stratified medicine, health economics, national professional and academic bodies/ 
committees. A process was devised based on Outcome Measures in Rheumatology Clinical 
Trials (OMERACT) principles to review aims/objectives, definition of scope, identification of 
important research questions, and selection of key domains.   
Results: Following the initial multi-stakeholder meeting, subsequent teleconferences and 
email communications, consensus was obtained on: 1. Most important and relevant research 
questions; 2. Agreement on how the OMERACT Core Areas (life impact, pathophysiological 
manifestations, resource use and death) could form the basis of a MCD; 3. Consensus on 22 
items for inclusion into a MCD.  Workshops were undertaken for two essential items which 
required further exploration: work/social participation and co-morbidity.  
Conclusions: Consensus for proposed minimal data items for long-term observational cohort 
studies of RA in the UK posed novel challenges and opportunities, and was largely successful. 
Further work is needed to select instruments for two important items and to achieve 
compatibility with other UK national initiatives, and more widely across Europe. 
 
Key messages: 
x Consensus was achieved for minimal data items for long-term observational cohort 
studies of RA  
x 22 demographic & clinical items using standard measures were agreed for a 
proposed MCD 
x Further work is needed on the appropriate instruments lacking for two important 
domains   
INTRODUCTION 
Longitudinal observational studies (LOS) provide data that many randomised controlled trials 
(RCTs) cannot capture, adding important insights to inform national drug commissioning and 
research bodies [1,2,3]. This is particularly relevant in the UK because the National Institute 
for Health and Clinical Excellence (NICE) adjudicates National Health Service (NHS) funded 
treatment strategies based largely on RCT data [4]  
 
Modelling long-term outcomes and health economic estimations of different therapeutic 
approaches requires additional exploration of observational datasets [5]. Data collected in 
UK RA cohorts and other countries varies in clinical features and laboratory markers 
depending on purposes of the study [6]. 
  
Different methods of data collection for apparently similar items and terminology make 
comparison between cohorts and meta-analyses challenging. Greater standardisation in data 
capture/reporting, patient consent and disease outcomes would facilitate data pooling and 
analysis across datasets/biobanks, reducing chances of biased interpretation.  
Increasing sample sizes by pooling studies would provide unprecedented opportunities to 
study less prevalent disease manifestations and subgroup analysis of important areas e.g. co-
morbidity in real-life settings, opening new possibilities for comparing disease trajectories, 
outcomes and therapeutic impacts.  
Towards this end, Arthritis Research UK (ARUK, a leading UK charity) commissioned 
development of a µPLQLPXPFore GDWDVHW¶ (MCD) for adult inflammatory arthritis (AIA), part of 
the larger INBANK project [7]. Linking patient information already recorded by the NHS to 
additional clinical information and tissue samples would promote national collaborative 
research into musculoskeletal conditions. Using AIA as an exemplar, a central component was 
development of a MCD that could be gathered prospectively from all observational datasets.  
 The concept of the MCD was to standardise data collection in LOS, irrespective of the primary 
research question in any one area of study, in order to facilitate maximal data exploitation for 
secondary analysis of RA outcomes by clinical and academic communities and UK regulatory 
authorities.  Any hospital could contribute, with additional data items optional for other projects. 
PHRSOHZLWKDQLQWHUHVWLQGHYHORSPHQWDQGDSSOLFDWLRQRIVWDQGDUGLVHG³FRUHRXWFRPHVHWV´
as described by COMET [8] were invited to participate in this process.  
 
Although the framework of the OMERACT consensus initiative to define a core outcome set 
[9] was developed specifically for RCTs, the principles are applicable to LOS. To ensure wide 
adoption, MCDs have to be simple, self-explanatory, clinically relevant and feasible in general 
outpatient settings in order to engage clinicians in both district hospital and research settings, 
without being overly burdensome and with wider application for future national or international 
projects. 
 
Although ARUK decided not to develop the infrastructure for the wider INBANK project, this 
first step towards a MCD for UK RA outcome studies has wider implications for LOS and was 
supported by the ARUK clinical studies group (CSG) [10]. We describe the process of deriving 
a provisional MCD for RA and its proposed content. Both might prove useful in facilitating 
greater research collaboration in RA and other disease areas. 
 
METHODS  
The remit was to harmonise data items that would be collected and ultimately mandated in 
future LOS in the UK; develop a sufficiently comprehensive dataset to address important 
research questions; complete the project within 12months on a limited budget. 
The elected project leads (AY, AM) invited well-established and appropriate experts from 
many institutions to represent the wide range of disciplines likely to use INBANK to form a 
development team.  
A process was adapted from OMERACT Filter 2.0 methodology [11], a recently-revised 
process of defining a core outcome set for clinical trials, and facilitated by two OMERACT 
representatives (MB, JK).  Consensus development was centred on three main stages 
(Fig1).  
Pre-defined break-out groups, based on appropriate mixes of patient partners, clinical and 
methodological expertise, with broad representation in each group, were given two specific 
tasks: identification of important research questions (both focused and broad) and candidate 
data items. 
It was agreed early on that the initial scope for AIA was too wide and should be confined to 
RA only. 
In order to maximise chances of including all relevant aspects, OMERACT Filter 2.0 explicitly 
separates the first step, identification of a Core Domain Set (what to measure), from the final 
definition of a Core Outcome Measurement Set (which includes how to measure). OMERACT 
advocates that at least one domain is chosen from each of four ³&RUH $UHDV´
pathophysiological manifestations; life impact; death; and resource use [11].  Instruments are 
subsequently selected to cover each Core Domain. 
Three sets of data were considered: basic identification (patient demographics), contextual 
factors (which could influence interpretation of outcomes) and individual outcome measures 
within overall core areas. 
The remainder of the development process evolved as teleconferences, emails and dedicated 
workshops where necessary. Summaries of each focused on items lacking consensus and 
appropriate measurement instruments until final agreement on all essential items was 
achieved.  
RESULTS 
The two main outcomes of this three-staged process were agreements of a key research 
question, and the minimum individual items for a MCD for RA which would address this and 
be feasible to collect in standard settings. 
Identifying the most suitable research question was based on one suitable for all stages of 
disease and answerable within a relatively short time-period.  The final question was 
purposefully broad and proposed to address ³:KDWSUHGLFWVFOLQLFDODQGKHDOWKRXWFRPHVRI
RA patients DWDOOVWDJHVRIGLVHDVH"´with the primary analysis focusing on ³:KDWSUHGLFWV
clinical and health outcomes of RA subjects with moderate disease activity (as defined using 
DAS28 3.2- DW DOO VWDJHV RI GLVHDVH"´ This was unanimously agreed to be important, 
relevant to all stakeholders and scientifically robust. It was endorsed independently and 
subsequently ratified by the ARUK AIA CSG at its annual strategy meeting in June 2013. 
,WZDVDJUHHGWKDWSDWLHQWVZLWKDFOLQLFLDQ¶VFRQVXOWDQWUKHXPDWRORJLVWfirm diagnosis of RA, 
irrespective of classification criteria or disease stage could be included, allowing for more 
homogeneous patient recruitment, examination of management issues over time, and less-
well researched aspects of disease e.g. less common long-term outcomes and co-morbidities. 
Emphasis was placed on items that could be collected feasibly in standard outpatient settings, 
and suitable and relevant for both early and established RA.  Individual domains under the 
four key OMERACT Areas were identified as potential candidates for a MCD. Stage 1 
identified 31 individual items as potential candidates, including demographics, important dates, 
contextual factors and domains from each of the four OMERACT areas. Of these, 14 items 
were initially proposed as essential components independently by all four discussion groups 
(Table 1). Agreement was not initially reached for the other 17 LWHPVLQGLFDWHGDVµSUREDEOH¶
!DJUHHPHQWRUµSRVVLEOH¶DJUHHPHQW 
Further discussions around items core to all RA studies and for specific stages of  disease  
resulted in the following (summarised in Table 1): µV\PSWRPRQVHW¶removed from the essential 
list because of doubtful accuracy and importance in established RA; 7 LWHPVLQWKHµSUREDEOH¶
category (weight, height, pain, fatigue, function, QoL/utility, co-morbidity) and two items in the 
non-essential category (smoking, family history) were finally agreed as essential items; 
consensus on 22 individual items for inclusion, three of which were imbedded in the EQ5D.   
Decisions on the majority of measurement instruments were straight-forward, based on well-
established validated tools. Absence of disease-specific validated tools was recognised for: 
participation/work; fatigue; and co-morbidity. Parallel small group teleconferences and/or 
dedicated workshops of team members played a key role on further decisions around these 
items.   Following an ARUK workshop on Fatigue, it was decided that a simple numerical rating 
scale (NRS) as opposed to a multi-dimensional instrument would be more appropriate for a 
minimal dataset. The 11-point NRS of the Bristol RA Fatigue Multi-Dimensional Questionnaire 
(BRAF MDQ) was agreed as most appropriate [12].  
Participants agreed that it would be reasonable to obtain consent for linkage for cause and 
date of death. In recognition of future opportunities for evaluating drug history and co-
morbidities as informatics systems become better integrated in the UK, linkage could also 
LQFOXGH WZR µSRVVLEOH LWHPV¶ hospital episodes and joint surgery, available from National 
Databases and Primary and Secondary Care Information Systems.   
 
Items identified as important for many research questions, but not essential for all, could be 
included in RSWLRQDO µDGG-RQ¶ VWXGLHV (Table 1).   ACR/EULAR classification criteria were 
excluded as they are not formally used by most clinicians in routine clinical practice and difficult 
to apply from notes review in established disease.   
 
The group distilled their combined opinions on the relative value and feasibility of collection 
based on clinical experience and discussion. All the provisional items considered have an 
evidence base as measures of, and predictors for, outcomes in RA. The development team 
included BSR representatives examining standard coding terms for rheumatic diseases to 
advise on precise definitions, clinical terms, validation rules and data entry consistency (e.g. 
dates). Figure 1 is a diagrammatic summary of the process. Table 1 shows agreed items for 
a MCD for RA, with corresponding instruments for data collection.  
Discussion  
Through the consensus process devised by OMERACT, the important initial step of agreeing 
a research question of universal interest was achieved by stakeholders, who also met the 
challenge to balance unfeasibly numerous measures against the need for the smallest 
possible dataset that could still answer a wide range of research questions robustly. The final 
research question agreed concerned outcomes of patients with moderate disease activity (and 
ineligible for biologics in the UK). It is notable that the AIA CSG independently identified the 
relative paucity of outcome data in moderate RA at the same time, and set this as a research 
priority for 2014/5.   
The group took into account SDWLHQWV¶SHUVSHFWLYHVDQGthe needs of clinical engagement with 
both district hospital and research-centre settings. The conceptual model underlying 
OMERACT Filter 2.0 methodology [11] was a crucial part of this multi-step process, resulting 
in successful step-wise selection of key domains under four Core Areas (life impact, death, 
pathophysiological manifestations and resource use), which firstly guided selection of core 
domains, and subsequently selection of appropriate candidate instruments. This strategy 
minimised the risk of missing out important domains.  
Twenty-two items were proposed as essential for a MCD (Table 1), consensus achieved 
through an opinion-based process. The absence of a formal multi-stage Delphi process 
because of time constraints could be considered a weakness. We believe these weaknesses 
were offset by achievement of the main aims of this initiative: the multi-disciplinary approach 
with wide ranges of expertise and backgrounds; compliance with concepts based on well-
established OMERACT methodology which includes step-wise approaches towards item 
selection based on existing evidence and expert opinion; strategic planning so that the process 
was completed within time and cost targets initially set out.  
Many of the MCD items are available within the NHS records system, but the domain 
measurements require clinical input. For two domains, participation/work and comorbidity, 
instruments for data-collection still need to be finalised. There was unanimous agreement that 
both should be embedded in routine data collection.  
The MCD-development process described here could prove beneficial towards standardising 
data collection, allowing comparisons and data pooling between cohorts and countries.  
Standardising outcomes has been proposed as a solution to the problems of inappropriate 
and non-uniform outcome selection in clinical trials [13]. OMERACT advocates use of core 
outcome sets in clinical trials designed using consensus techniques [14] which formed the 
basis of the current process for a provisional MCD, albeit focussed on LOS in RA.  
Our provisional dataset requires validation in routine clinical settings. Work is currently in 
progress both nationally & internationally on easily administered and validated measures for 
participation/work and co-morbidity. Close liaison with BSR will avoid duplicate work streams 
and maximise levels of consistency between datasets on clinical terms and data entry for all 
items. 
In conclusion, the development of a provisional list of minimum data items (including core 
outcome domains and their instruments) for LOS and research databases in RA has posed 
novel challenges and opportunities. The process followed was largely successful, achieved in 
less than 12months, and could help development of larger-scale projects and in other disease 
areas.  Well-coordinated data capture with national linkage where possible could be an 
important way forward, optimising data for research which would have an ultimate impact on 
patient care.  
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